Eikonoklastes Therapeutics, Inc.

eikonoklastes is advancing a new generation of tissue factor (tf) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment. it has recently been discovered that certain pathological cells – but not healthy cells – including cancers with high unmet need and high mortality such as triple-negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors, express tissue factor on the surface of their cell membranes. several other non-cancerous indications such as endometriosis also highly and selectively express tissue factor.